| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.UROLONC.2014.11.020 |
| P698 | PubMed publication ID | 25596644 |
| P50 | author | Eugene K. Cha | Q37839556 |
| P2093 | author name string | James A Eastham | |
| P2860 | cites work | Sipuleucel-T immunotherapy for castration-resistant prostate cancer | Q27860648 |
| Cancer statistics, 2014 | Q27861018 | ||
| Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer | Q29616123 | ||
| Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer | Q29616218 | ||
| Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial | Q29620155 | ||
| Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer | Q31967563 | ||
| Application of oligonucleotide microarrays to assess the biological effects of neoadjuvant imatinib mesylate treatment for localized prostate cancer | Q33231043 | ||
| Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate cancer. | Q33759217 | ||
| Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer | Q34226107 | ||
| Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer | Q34435524 | ||
| Preoperative versus postoperative chemoradiotherapy for rectal cancer | Q34552041 | ||
| International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial | Q35023400 | ||
| Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease | Q35640625 | ||
| Short-term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with high-risk local | Q35704002 | ||
| Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial | Q37218730 | ||
| Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer | Q37309238 | ||
| Phase II trial of neoadjuvant docetaxel and CG1940/CG8711 followed by radical prostatectomy in patients with high-risk clinically localized prostate cancer | Q39143417 | ||
| Long-term follow-up of 3-month neoadjuvant hormone therapy before radical prostatectomy in a randomized trial | Q42147892 | ||
| Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer | Q42168730 | ||
| Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer | Q42593734 | ||
| Changing nature of high risk patients undergoing radical prostatectomy | Q44006823 | ||
| Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial | Q44070350 | ||
| Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial | Q44282879 | ||
| Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locally advanced prostate cancer. | Q44387038 | ||
| Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy | Q44546063 | ||
| Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: results of a phase I/II study | Q44721034 | ||
| Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer | Q44926809 | ||
| Phase II trial of neoadjuvant docetaxel and gefitinib followed by radical prostatectomy in patients with high-risk, locally advanced prostate cancer | Q44944280 | ||
| Neoadjuvant platelet derived growth factor receptor inhibitor therapy combined with docetaxel and androgen ablation for high risk localized prostate cancer | Q46243532 | ||
| Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer | Q46539730 | ||
| A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer | Q46689589 | ||
| Neoadjuvant chemohormonal therapy in poor-prognosis localized prostate cancer | Q46727594 | ||
| Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. | Q46765380 | ||
| A phase II clinical trial of neoadjuvant ketoconazole and docetaxel chemotherapy before radical prostatectomy in high risk patients. | Q51018938 | ||
| Phase II trial of neoadjuvant nab-paclitaxel in high risk patients with prostate cancer undergoing radical prostatectomy. | Q51810500 | ||
| Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. | Q54516956 | ||
| Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer | Q57259796 | ||
| Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results | Q73492611 | ||
| Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods | Q80461562 | ||
| Neoadjuvant docetaxel treatment for locally advanced prostate cancer: a clinicopathologic study | Q80733052 | ||
| Prostate cancer, version 2.2014 | Q87842508 | ||
| P433 | issue | 5 | |
| P921 | main subject | prostate cancer | Q181257 |
| P304 | page(s) | 217-225 | |
| P577 | publication date | 2015-01-14 | |
| P1433 | published in | Urologic Oncology | Q2113446 |
| P1476 | title | Chemotherapy and novel therapeutics before radical prostatectomy for high-risk clinically localized prostate cancer | |
| P478 | volume | 33 |
| Q38555599 | Chemotherapy in Prostate Cancer |
| Q95262848 | Identifying the relevant population for neoadjuvant chemo-hormonal therapy combined with radical prostatectomy |
| Q36129003 | Low density lipoprotein receptor targeted doxorubicin/DNA-Gold Nanorods as a chemo- and thermo-dual therapy for prostate cancer |
| Q38728163 | Molecular mechanism of prostate cancer cell apoptosis induced by busulfan via adjustment of androgen receptor phosphatization |
| Q38770371 | Neoadjuvant Treatment of High-Risk, Clinically Localized Prostate Cancer Prior to Radical Prostatectomy |
| Q92991279 | Neoadjuvant chemohormonal therapy combined with radical prostatectomy and extended PLND for very high risk locally advanced prostate cancer: A retrospective comparative study |
| Q47329081 | Overall survival of high-risk prostate cancer patients who received neoadjuvant chemohormonal therapy followed by radical prostatectomy at a single institution |
| Q36879999 | Prostate MRSI predicts outcome in radical prostatectomy patients |
| Q39356209 | Radical Prostatectomy for High-risk Localized or Node-Positive Prostate Cancer: Removing the Primary. |
| Q49567841 | Radical prostatectomy in locally advanced prostate cancer |
| Q53681749 | Systemic treatments for high-risk localized prostate cancer. |
| Q26770247 | Taxane Chemotherapy for Hormone-Naïve Prostate Cancer with Its Expanding Role as Breakthrough Strategy |
| Q36738908 | The pepper's natural ingredient capsaicin induces autophagy blockage in prostate cancer cells |
| Q83547408 | The role of cystoprostatectomy in management of locally advanced prostate cancer: a systematic review |
| Q38841717 | Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features |
| Q37685889 | Waist-hip Ratio (WHR), a Better Predictor for Prostate Cancer than Body Mass Index (BMI): Results from a Chinese Hospital-based Biopsy Cohort. |
| Q89995929 | mpMRI preoperative staging in men treated with antiandrogen and androgen deprivation therapy before robotic prostatectomy |
Search more.